Nutex Health (NASDAQ:NUTX) Announces Earnings Results, Misses Estimates By $3.95 EPS

Nutex Health (NASDAQ:NUTX) issued its quarterly earnings results on Thursday. The company reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.56 by ($3.95), Zacks reports. Nutex Health had a return on equity of 18.70% and a net margin of 7.34%.The business had revenue of $151.68 million for the quarter, compared to analysts’ expectations of $258.82 million.

Nutex Health Trading Down 14.3%

NUTX stock opened at $90.28 on Friday. The company has a current ratio of 3.20, a quick ratio of 3.18 and a debt-to-equity ratio of 0.67. Nutex Health has a 12-month low of $40.67 and a 12-month high of $193.07. The stock has a market cap of $638.28 million, a price-to-earnings ratio of 10.05 and a beta of 0.03. The business’s 50-day moving average is $136.67 and its 200 day moving average is $124.50.

More Nutex Health News

Here are the key news stories impacting Nutex Health this week:

• Positive Sentiment: Nutex reported strong full‑year 2025 results (revenue +82% y/y to $875.3M; net income and EPS up; adjusted EBITDA +152.6%) and announced a second stock repurchase program — news that can support the stock over time by reducing share count and signaling management confidence. NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM
• Positive Sentiment: Analyst/coverage pieces are discussing valuation upside given earnings growth and the buyback, which may attract long‑term investors focused on fundamentals. Assessing Nutex Health (NUTX) Valuation After Earnings Growth And New Share Buyback Program
• Neutral Sentiment: Corporate press releases and financial filings provide the detailed numbers and management commentary — useful for investors doing due diligence but unlikely to move the market on their own. Company Press Release / Financial Report
• Negative Sentiment: Nutex’s most recent quarterly report missed expectations sharply (EPS $1.61 vs. $5.56 est.; revenue $151.7M vs. $258.8M), a short‑term catalyst for selling as it signals volatility in recent revenue drivers. MarketBeat: Earnings Summary
• Negative Sentiment: Multiple law firms (Block & Leviton, Kuehn Law and others) have launched investigations or encouraged shareholders to contact them over potential securities fraud and fiduciary‑duty claims tied to disclosure of revenue recognition and internal controls — a major overhang that raises litigation risk, potential settlements, and reputational damage. Block & Leviton Investigation Notice
• Negative Sentiment: Additional press items detail similar shareholder litigation allegations about HaloMD-related revenue recognition, internal control weaknesses, and stock‑based compensation treatment — issues that could lead to restatements or future liabilities. Kuehn Law Notice
• Negative Sentiment: Local/regional reporting highlights investor outreach from law firms, amplifying negative headlines and short‑term selling pressure. GazetteXtra: Investor Advisory

Hedge Funds Weigh In On Nutex Health

Several hedge funds and other institutional investors have recently made changes to their positions in NUTX. BNP Paribas Financial Markets boosted its stake in shares of Nutex Health by 966.7% in the second quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock worth $40,000 after acquiring an additional 290 shares during the last quarter. Royal Bank of Canada raised its stake in Nutex Health by 752.4% in the 4th quarter. Royal Bank of Canada now owns 358 shares of the company’s stock valued at $59,000 after purchasing an additional 316 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in Nutex Health by 280.3% in the 4th quarter. Osaic Holdings Inc. now owns 810 shares of the company’s stock valued at $133,000 after purchasing an additional 597 shares in the last quarter. Vestcor Inc purchased a new position in Nutex Health in the 3rd quarter valued at $111,000. Finally, New York State Common Retirement Fund acquired a new stake in Nutex Health during the 2nd quarter worth $137,000. Hedge funds and other institutional investors own 5.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on NUTX shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Nutex Health in a research note on Monday, December 29th. Wall Street Zen cut shares of Nutex Health from a “strong-buy” rating to a “hold” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $252.50.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.